Wolfgang Miesbach/LinkedIn
Apr 23, 2026, 03:17
Wolfgang Miesbach: The Haemophilia A Gene Therapy Story Is Moving from West to China
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”The haemophilia A gene therapy story is not over – it is moving from West to China:
West: BioMarin is withdrawing Roctavian from the global market after failing to divest the product, marking a major commercial retreat from this first‑in‑class AAV5 FVIII gene therapy.
China: GS1191‑0445 (AAV8, liver-directed) continues to advance, with new multi‑year data in 76 adults with severe haemophilia A presented by Dr. Wei Liu at WFH 2026.
- Doses: 2×10¹²–4×10¹² vg/kg
- Mean FVIII:C approximately 45 IU/dL at 2 years (3×10¹² vg/kg)
- ABR reduced by up to 99.4% vs baseline
- Zero spontaneous bleeds over 52 weeks at 3×10¹² and 4×10¹²
- No thrombotic events, no inhibitors; TEAEs mostly grade 1–2 under prophylactic prednisone plus tacrolimus
Durable multi‑year expression and near‑elimination of bleeding remain realistic goals.”
Stay updated with Hemostasis Today.
-
Jun 16, 2026, 15:4910 Posts Not To Miss From EHA 2026
-
Jun 16, 2026, 15:48Yan Leyfman: Can a Blood Test Reveal which Cells in Your Body are Aging Fastest?
-
Jun 16, 2026, 15:24Hiteshi K.C. Chauhan: Oral Anticoagulant Reversal in Major Bleeding and Urgent Surgery
-
Jun 16, 2026, 14:50Abdulrahman Nasiri: Honored to Share our Research Contributions at the EHA 2026
-
Jun 16, 2026, 14:49An Overview of Bernard–Soulier Syndrome – ICHCC
-
Jun 16, 2026, 14:47David Walcott: Blood Supply as Essential Healthcare Infrastructure
-
Jun 16, 2026, 14:36Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
-
Jun 16, 2026, 14:30Jeffrey Kallberg: Education and Advocacy at the Texas Bleeding Disorders Conference
-
Jun 16, 2026, 14:23Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency